DM has received per diem, including speaking fees, from Janssen Pharmaceutical, Chugai Pharmaceutical, Kyowa Kirin, Eisai, AstraZeneca, SymBio Pharmaceuticals, and Takeda Pharmaceuticals; and has received research funding from Novartis Pharma, Chugai Pharmaceutical, Ono Pharmaceutical, Takeda Pharmaceuticals, Janssen Pharmaceutical, MSD, Loxo Oncology, Bristol Myers Squibb, Kyowa Kirin, Otsuka Pharmaceutical, and IQVIA Services Japan. MY has no conflicts of interest to report.